United Therapeutics Corp

Latest Results (11.11.2025):

United Therapeutics Corp reported its First Quarter 2025 Financial Results with record revenue performance and solid earnings growth. In this quarter, the company achieved $794.4 million in total revenues—a 17% increase from Q1 2024—and a net income of $322.2 million, up 5% year-over-year. The basic earnings per share rose from $6.52 to $7.18, reflecting a 10% improvement. The results also highlighted robust performance in key products such as Tyvaso (with significant gains in both DPI and nebulized forms) and steady growth in Remodulin and Orenitram, while also noting increased investments in research and development as well as selling, general, and administrative expenses.

Record Revenue Performance

The first quarter of 2025 saw United Therapeutics Corp generate $794.4 million in revenues, marking an increase of $116.7 million or 17% compared to Q1 2024. This record performance underlines the strength of their commercial strategy, particularly in the pulmonary hypertension marketplace.

Improved Earnings and EPS

Net income increased to $322.2 million in Q1 2025, a 5% rise over the previous year, with basic EPS increasing by 10% to $7.18. These improvements reflect operational efficiencies and heightened sales across key product lines.

Strong Product Sales Growth

Sales from major therapeutic products drove the revenue gain; Tyvaso DPI and its nebulized version led with increases of 33% and 13% respectively, contributing to a 25% boost in total Tyvaso revenues. Remodulin and Orenitram also experienced notable sales volume upticks, reinforcing the company’s market position.

Increased Investments in R&D and SG&A

R&D expenses jumped 43% year-over-year, driven by both internal and external projects supporting the company’s innovation wave. Additionally, selling, general, and administrative expenses increased by 18% as United Therapeutics expanded its headcount and commercial activities to support its growth strategy.